[go: up one dir, main page]

MX2016016071A - Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. - Google Patents

Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.

Info

Publication number
MX2016016071A
MX2016016071A MX2016016071A MX2016016071A MX2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A
Authority
MX
Mexico
Prior art keywords
nicotinamide riboside
branched
straight chain
pharmaceutical compositions
disorder
Prior art date
Application number
MX2016016071A
Other languages
English (en)
Inventor
Robert B Perni
Bruce Szczepankiewicz
Koppetsch Karsten
PREUGSCHAT Frank
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of MX2016016071A publication Critical patent/MX2016016071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

En la presente memoria se proporcionan análogos de éster y carbonato de ribósido de nicotinamida y de hidruro de ribósido de nicotinamida estereoisoméricamente puros, y composiciones farmacéuticas y usos de los mismos; los análogos de éster y carbonato de ribósido de nicotinamida y de hidruro de ribósido de nicotinamida estereoisoméricamente puros pueden usarse para tratar una enfermedad o trastorno que podría beneficiarse de los niveles de NAD aumentados, incluyendo una enfermedad o trastorno mitocondrial, resistencia a la insulina, un síndrome metabólico, diabetes, obesidad, para aumentar la sensibilidad a la insulina en un sujeto, o para tratar o prevenir una afección cutánea; los compuestos tienen fórmulas generales (I) o (II) en donbde R1 es -C(=0)-X-alquilo (C2-C18 de cadena lineal o ramificada) o -C(.=0)-X-alquenilo (C2-C18 de cadena lineal o ramificada); cada R2 se selecciona independientemente entre hidrógeno, y un -C(0)-X-alquilo (C2-C18 de cadena lineal o ramificada) o un -C(0)-X-alquenilo (C2-C18 de cadena lineal o ramificada); y X es un enlace covalente u O. (FORMULAS).
MX2016016071A 2014-06-06 2015-06-05 Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. MX2016016071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008707P 2014-06-06 2014-06-06
PCT/IB2015/054281 WO2015186114A1 (en) 2014-06-06 2015-06-05 Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2016016071A true MX2016016071A (es) 2017-07-11

Family

ID=53398163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016071A MX2016016071A (es) 2014-06-06 2015-06-05 Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.

Country Status (11)

Country Link
US (1) US10485814B2 (es)
EP (1) EP3152220A1 (es)
JP (1) JP6559713B2 (es)
KR (1) KR20170008320A (es)
CN (1) CN106715455A (es)
AU (1) AU2015270090A1 (es)
BR (1) BR112016028672A2 (es)
CA (1) CA2951287A1 (es)
MX (1) MX2016016071A (es)
RU (1) RU2016149767A (es)
WO (1) WO2015186114A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
PL3670522T3 (pl) 2014-07-24 2022-02-21 W.R. Grace & Co. - Conn. Krystaliczna postać chlorku rybozydu nikotynamidu
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
EP3288529A1 (en) * 2015-05-01 2018-03-07 The Procter and Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
EP3322419B1 (en) 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
PL3331894T3 (pl) 2015-08-05 2021-08-23 Metro International Biotech, Llc Pochodne mononukleotydu nikotynamidowego i ich zastosowania
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
ES2812456T3 (es) * 2015-12-21 2021-03-17 Showa Denko Kk Derivado de mononucleótido de nicotinamida y sal del mismo, método para producir el mismo, agente tópico, cosmético y aditivo alimentario
WO2017123512A1 (en) * 2016-01-11 2017-07-20 The Procter & Gamble Company Method of treating a skin condition and compositions therefor
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
ES2948968T3 (es) * 2016-04-20 2023-09-22 Chromadex Inc Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++
JP7166636B2 (ja) 2016-07-15 2022-11-08 エイチツー ウォーター テクノロジーズ リミテッド 水素豊富水を生成するための組成物及び他の製品
GB2553001A (en) * 2016-08-19 2018-02-21 The Queen's Univ Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
CN120463761A (zh) 2016-11-11 2025-08-12 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018132833A1 (en) * 2017-01-13 2018-07-19 The Regents Of The University Of Colorado, A Body Corporate Methods for treating hypertension and arterial stiffness
HUE055521T2 (hu) * 2017-04-05 2021-11-29 Univ Cornell Béta-nikotinát-észter nukleotidok és eljárás azok elõállítására
WO2018200357A1 (en) * 2017-04-26 2018-11-01 Elysium Health, Inc. Methods and compositions of improving fertility
US20200179441A1 (en) * 2017-04-27 2020-06-11 H2 Water Technologies Ltd. Synergistic compositions for increasing mitochondrial function and energy
WO2018236814A2 (en) * 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
CN114788791A (zh) 2017-06-23 2022-07-26 宝洁公司 用于改善皮肤外观的组合物和方法
US20200330497A1 (en) * 2017-10-19 2020-10-22 Elysium Health, Inc. Prevention and treatment of tdp-43 associated diseases
US20200261483A1 (en) * 2017-10-30 2020-08-20 Elysium Health, Inc. Methods and compositions for treating cystic fibrosis
WO2019108878A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
US11815515B2 (en) * 2018-01-17 2023-11-14 University Of Southampton Methods to predict risk of and to stratify sarcopenia and NAD deficiency
CN113396153B (zh) * 2018-05-15 2025-08-05 江普斯塔特生育有限公司 作为抗衰老剂的烟酸单核苷酸和烟酰胺单核苷酸的氨基酸盐
US20210196742A1 (en) * 2018-05-22 2021-07-01 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
EP4497474A3 (en) * 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
KR20220013540A (ko) 2019-02-21 2022-02-04 크로마덱스 아이엔씨. 니코틴아미드 리보사이드, 니코틴산 리보사이드, 환원 니코티닐 리보사이드 화합물, 및 니코티닐 리보사이드 화합물 유도체의 제형에서의 용도
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US20220249535A1 (en) * 2019-04-05 2022-08-11 Rejuvenation Therapeutics Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof
JP7610531B2 (ja) * 2019-06-05 2025-01-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド
JP2022534872A (ja) * 2019-06-05 2022-08-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 肝疾患の治療のための還元型ニコチンアミドリボシド
US20220233565A1 (en) * 2019-06-05 2022-07-28 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
CN114555619A (zh) * 2019-08-14 2022-05-27 麦德龙国际生物科技有限责任公司 用于烟酰胺腺嘌呤二核苷酸的差分调节的化合物和组合物
FR3103702B1 (fr) * 2019-11-28 2022-02-11 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
CN110755432A (zh) * 2019-12-02 2020-02-07 浙江大学 烟酰胺在制备治疗手足皮肤反应制剂中的应用
FR3107897B1 (fr) * 2020-03-06 2023-05-26 Nuvamid Sa Dérivés de nicotinamide mononucléotides
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
US20230095103A1 (en) * 2020-03-09 2023-03-30 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
FR3108032B1 (fr) * 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
FR3108031B1 (fr) * 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
JP7792915B2 (ja) * 2020-04-07 2025-12-26 アステラス エンジニアード スモール モレキュールズ ユーエス インコーポレイテッド Ｃｄ３８阻害薬
WO2021214299A1 (en) * 2020-04-24 2021-10-28 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
EP3901160A1 (en) * 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021231874A1 (en) * 2020-05-15 2021-11-18 Psimos, Inc Composition for growth stimulation and resistance to stress factors for plants of the cannabaceae family
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US20230255994A1 (en) * 2020-07-01 2023-08-17 Metro International Biotech, Llc Treatment of covid-19 and/or acute kidney injury
CN114053292A (zh) * 2020-07-31 2022-02-18 高志玲 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型
CA3187851A1 (en) * 2020-08-07 2022-02-10 Guillaume BERMOND Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
CN117377480A (zh) * 2020-10-14 2024-01-09 音芙医药科技(上海)有限公司 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CA3206030A1 (en) * 2020-12-18 2022-06-23 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
KR102323400B1 (ko) * 2021-03-26 2021-11-09 (주)아이엠디팜 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물
BR112023024712A2 (pt) * 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
CN113308436A (zh) * 2021-06-24 2021-08-27 海南赛奥干细胞生物科技有限公司 一种人类骨髓、脐带血干细胞处理试剂盒及干细胞分离方法
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
IL310096A (en) * 2021-07-12 2024-03-01 Cytokinetics Inc CD38 modulators and methods of using them
WO2023052573A1 (en) * 2021-09-30 2023-04-06 Société des Produits Nestlé S.A. Nicotinamide riboside trioleates chloride, compositions containing this compound, and methods of making and using this compound
CN115304655B (zh) * 2021-11-23 2024-11-22 中立安(北京)医药科技有限公司 烟酰胺单核苷类衍生物及其制备方法和应用
CN115232184B (zh) * 2021-12-06 2024-07-05 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物及其药物组合物和用途
CN115400140B (zh) * 2022-01-27 2024-02-20 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途
WO2023154844A2 (en) * 2022-02-10 2023-08-17 Workman David Henry Compositions comprising nad+ and associated methods of treatment
WO2024123296A1 (en) * 2022-12-07 2024-06-13 Atatürk Üni̇versi̇tesi̇ Rektörlüğü Bi̇li̇msel Araştirma Projeleri̇ (Bap) Koordi̇nasyon Bi̇ri̇mi̇ A compound containing nicotinamide riboside to inhibit cyst formation and induce ovulation in polycystic ovary syndrome
WO2025160321A1 (en) * 2024-01-24 2025-07-31 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative disease
WO2025192761A1 (ko) * 2024-03-12 2025-09-18 주식회사 레미바이오 니코틴아마이드 아데닌 디뉴클레오타이드 유도용 화합물, 이를 포함하는 조성물 및 피부 외용제
CN119143825A (zh) * 2024-11-18 2024-12-17 温州市人民医院 一种抗衰老的nmn衍生物及其制备工艺和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798076A (en) 1952-03-14 1957-07-02 Hoffmann La Roche 1-isonicotinyl-2-hydroxyalkylhydrazines
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
PT1027359E (pt) 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
DK1143954T3 (da) 1998-12-01 2004-12-20 Univ Kentucky Res Found Anvendelse af nicotinsyrederivater til behandling af DNA-skade i hudceller
AU2350800A (en) 1998-12-01 2000-06-19 University Of Kentucky Research Foundation, The Method for prevention of photocarcinogenesis and photoimmunosuppression
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
AU2001257063B2 (en) 2000-04-14 2005-04-28 Myron K. Jacobson Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2007530417A (ja) 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2005077091A2 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
US20050227327A1 (en) 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
US7776326B2 (en) 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
MX2009008022A (es) 2007-01-26 2009-12-11 Univ Washington Metodos y composiciones para tratar neuropatias.
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2273992B1 (en) 2008-05-01 2016-05-25 Glaxosmithkline LLC Quinolines and related analogs as sirtuin modulators
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
EP2364698A4 (en) 2008-07-25 2011-09-14 Snu R&Db Foundation COMPOSITION AGAINST AGING AND / OR LENGTHENING DURATION, CONTAINING DAPSONE AS ACTIVE INGREDIENT
ES2517690T3 (es) 2008-09-29 2014-11-03 Glaxosmithkline Llc Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina
EP2376502B1 (en) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridine sirtuin modulating compounds
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
WO2012094343A1 (en) * 2011-01-05 2012-07-12 Trilink Biotechnologies Chemically substituted thermosensitive probes and cofactors for hot start ligation
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
CN104011053A (zh) 2011-10-20 2014-08-27 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
KR20140077965A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
KR20220098049A (ko) 2013-10-30 2022-07-08 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Also Published As

Publication number Publication date
RU2016149767A (ru) 2018-07-16
AU2015270090A1 (en) 2016-12-22
BR112016028672A2 (pt) 2017-08-22
JP6559713B2 (ja) 2019-08-14
US10485814B2 (en) 2019-11-26
CN106715455A (zh) 2017-05-24
JP2017516833A (ja) 2017-06-22
US20170189433A1 (en) 2017-07-06
KR20170008320A (ko) 2017-01-23
EP3152220A1 (en) 2017-04-12
WO2015186114A1 (en) 2015-12-10
CA2951287A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2016016071A (es) Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
CU24183B1 (es) Derivados de ácido 3-fenilpropiónico ramificados
BR112014029754A2 (pt) soluções de tensoativos contendo n-metil-n-oleilglucaminas e n-metil-n-c12-c14-acilglucaminas
BR112013020513A2 (pt) adoçante stevia altamente solúvel
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
GT201300208A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
MX348564B (es) Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos.
MY169745A (en) Purinone derivative
UY33758A (es) Acidos indaniloxidihidrobenzofuranilaceticos
NZ743706A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CO7350620A2 (es) Nuevos derivados de piridina
PE20142359A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112014029781A2 (pt) soluções de tensoativos contendo n-metil-n-c8-c10-acilglucaminas e n-metil-n-c12-c14-acilglucaminas
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
ZA202102438B (en) Melflufen dosage regimens for cancer
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia
IN2014DN08582A (es)
AR086647A1 (es) Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
MX370884B (es) Derivados de catecolamina enriquecidos con deuterio asimétrico posición-específico y medicamentos que comprenden los compuestos.
PH12013501778A1 (en) Chemical composition with hydrogen peroxide and a nanoemulsion of long-chained alcohols
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
TW201129357A (en) Novel compound, antitumor agent, and medicines, food or cosmetics with antitumor action
AR068978A1 (es) N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof